Antiva wants to help treat cervical cancer. Most male investors aren't interested.


A young pharmaceutical startup wants to develop a groundbreaking new treatment for a relatively common cancer. Yet it struggles to find funding.
That's because the startup in question is Antiva Biosciences, and the cancer it aims to treat is cervical cancer. Stat reported Thursday on the company's struggles to attract investment, as well as its constant fight to receive buy-in from male doctors, quoting Antiva's top executives discussing frankly their perceptions of the problem: "It's very safe to say that we got more traction in [venture capital] firms where there was a woman partner who was in a decision-making role," Antiva CEO Gail Maderis told Stat.
Antiva's proposal is to replace the most common treatment prescribed for women who develop the precancerous cervical lesions that result from being infected with HPV, which is surgery. The operation removes the lesions by "essentially cutting off the tip of the cervix," Stat reports. The surgery has proven effective in eradicating the problem cells, but "women of childbearing age who undergo the surgery may later have difficulty conceiving, recurrent miscarriages, and preterm delivery," Stat explains.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Antiva says about 500,000 women undergo this procedure every year. Instead of surgery, the company is proposing a topical treatment that patients can administer themselves. But the reception has been lukewarm: Maderis told Stat of how one prospective male investor who appeared unenthused during Maderis' pitch. But after their meeting, he called Maderis to explain how his wife had pressed him to investigate the deal further after he'd told her about the company's mission.
One man, David Kabakoff, did invest in Antiva through his firm. His team has been calling gynecologists to glean their reactions to the topical treatment. "The trend was unmistakable," Stat wrote: "Male physicians tended to express skepticism ... Female physicians tended to say new treatment options are badly needed." Read more about Antiva at Stat.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kimberly Alters is the news editor at TheWeek.com. She is a graduate of the Medill School of Journalism at Northwestern University.
-
Jasveen Sangha and the ketamine 'Wild West' of Hollywood
In The Spotlight Arrest of the 'ketamine queen' accused of supplying Friends star Matthew Perry with deadly dose has turned spotlight on a showbiz drug problem
-
Confessions of a Brain Surgeon: an 'exceptional' documentary
The Week Recommends Retired neurosurgeon Henry Marsh reflects on his pioneering work with exquisitely 'raw honesty'
-
A new subtype of diabetes was found and it may require different treatment
Under the radar It is prevalent in Black Africans and Americans
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages